Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Immuneering Corporation Class A Common Stock
IMRX | US
2.16
USD-0.08
-3.57%
IMRX | US
About Immuneering Corporation Class A Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
2.16
Open
2.20
High
2.21
Low
2.08
Immuneering Corporation a clinical-stage oncology company engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104 a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer including pancreatic melanoma colorectal and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge Massachusetts.
View LessIMRX | US
Risk
103.4
Sharpe
-0.49
Luna's Score
40/100
Recommendation
Sell
Luna says (IMRX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
112.1%1 month
103.4%3 months
167.6%6 months
136.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.93
Debt to equity
0.07
Debt to assets
0.06
Ent. to EBITDA
-1.53
Ent. to rev.
191.91K
PEG
-
Other Fundamentals
EBITDA
-60.09M
MarketCap
64.05M
MarketCap(USD)
64.05M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-99.80
Ret. on equity
-61.81
Short ratio
0.11
Short perc.
7.40
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.70
Range1M
1.45
Range3M
2.83
Volumes: Market Activity
Rel. volume
0.13
Price X volume
753.23K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.53 | 0.53 | Cheaper |
| Ent. to Revenue | 191,914.00 | 3,967.00 | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.93 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 167.60 | 72.80 | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 64.05M | 3.66B | Emerging |
